AACR 2014 - Pharmaco-imaging study of the effects of Debio1143, a new orally available IAP inhibitor, in a triple-negative breast cancer model
Centre Georges-François Leclerc, Oncodesign, Debiopharm International SA, ICMUB
Centre Georges-François Leclerc, Oncodesign, Debiopharm International SA, ICMUB
Isarna Therapeutics GmbH, Oncodesign
Oncodesign, Centre Georges-François Leclerc, Molecular Partners AG
Oncodesign, In-Vivo Sciences Inc, CIEA